TNF-α and G-CSF induce CD62L and CD106 expressions on rat bone marrow-derived MSCs

Xing Liu 1 , Yang Ming 2 , Ligang Chen 2 , Lilei Peng 2 , Qiang Ye 1 , Shuzhan Zheng 1  and Zhongcai Fan 1
  • 1 Department of Cardiology, The Affiliated Hospital, Luzhou Medical College, Luzhou 646000, Sichuan Province, China
  • 2 Department of Neurosurgery, The Affiliated Hospital, Luzhou Medical College, Luzhou 646000, Sichuan Province, China


Background: Accumulating evidence suggests that CD62L and CD 106 are positively expressed on the surface of mesenchymal stem cells (MSCs). It has been reported that both receptors can be induced by minor necrosis factor- ⃞ (TNF-α). granulocyte-colony stimulating factor (G-CSF). and vascular endothelial growth factor (VEGF) on leucocytes. However, whether these stimulations induce CD62L and CD 106 expressions on MSCs is still unknown. Thus, in the present study we investigated the effects of TNF-α. G-CSF and VEGF on CD62L and CD 160 expressions on the surface of MSCs.

Method: MSCs were isolated from rat bone marrows, and treated with different concentrations of TNF-α (0.1.1 and 10 ng/mL), G-CSF and VEGF (1.10. and 100 ng/mL) for 12 and 24 hours respectively. Then the expressions of CD62L and C'D 106 on the surface of MSCs were analyzed by flow cytometry.

Results: Immunochemistry assay showed positive CD90 but negative CD45 in the MSCs. Flow cytometry analysis suggested that TNF-α and G-CSF could induce CD62L and CD106 expressions on the surface of MSCs in a dose-dependent manner, but not in a time-dependent manner. Further, all the concentrations of VEGF had no significant effect on the CD62L and CD106 expressions.

Conclusion: CD62L and CD106 can be induced by TNF-α and G-CSF on the surface of MSCs. but not by VEGF. These findings can help improve BM-MSC migration capability and therapeutic efficiencies of MSC transplantation.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Bolan-Meade J, Vogelsang GB. Mesenchymal stem cells and organ transplantation: current status and promising future. Transplantation. 2006; 81:1288-389.

  • 2. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology. 2007; 11:1-6.

  • 3. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infracted myocardium. Nature. 2001; 410:701-5.

  • 4. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011; 14:211-5.

    • Crossref
    • Export Citation
  • 5. Volarevic V, Arsenijevic N, Lukic ML. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 2011; 29:5-10.

    • Crossref
    • Export Citation
  • 6. Bao X, Wei J, Feng M, Lu S, Li G, Dou W, et al. Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res. 2011; 1367:103-13.

  • 7. Song SW, Chang W, Song BW, Song H, Lim S, Kim HJ, et al. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem cells. 2009; 27:1358-65.

    • Crossref
    • Export Citation
  • 8. Nishihira S, Okubo N, Takahashi N, Ishisaki A, Sugiyama Y, Chosa N. High-cell density-induced VCAM1 expression inhibits the migratory ability of mesenchymal stem cells. Cell Biol Int. 2011; 35:475-81.

  • 9. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M, et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol. 2008; 44: 281-92.

  • 10. Grailer JJ, Kodera M, Steeber DA. L-selectin: Role in regulating homeostasis and cutaneous inflammation. J Dermatol Sci. 2009; 56:141-7.

  • 11. Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, et al. Optimization of a flow cytometrybased protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry B Clin Cytom. 2006; 70:391-9.

    • Crossref
    • Export Citation
  • 12. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004; 95:9-20.

  • 13. Toyama K, Honmou O, Harada K, Suzuki J, Houkin K, Hamada H, et al. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol. 2009; 16:47-55.

    • Crossref
    • Export Citation
  • 14. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006; 355:1199-209.

  • 15. Johnson TV, Bull ND, Martin KR. Identification of barriers to retinal engraftment of transplanted stem cells. Invest Ophthalmol Vis Sci. 2010; 51:960-70.

  • 16. Lundberg J, Le Blanc K, Soderman M, Andersson T, Holmin S. Endovascular transplantation of stem cells to the injured rat CNS. Neuroradiology. 2009; 51:661-7.

  • 17. Kan I, Melamed E, Offen D. Integral therapeutic potential of bone marrow mesenchymal stem cells. Curr Drug Targets. 2005; 6:31-41.

    • Crossref
    • Export Citation
  • 18. Herrmann JL, Abarbanell AM, Weil BR, Wang Y, Poynter JA, Manukyan MC, et al. Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function. Am J Physiol Regul Integr Comp Physiol. 2010; 299: R371-R378.

  • 19. De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, et al. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica. 2007; 92:440-9.


Journal + Issues